Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Jan Cerny"'
Autor:
Michael Boyiadzis, Mei-Jie Zhang, Karen Chen, Hisham Abdel-Azim, Muhammad Bilal Abid, Mahmoud Aljurf, Ulrike Bacher, Talha Badar, Sherif M. Badawy, Minoo Battiwalla, Nelli Bejanyan, Vijaya Raj Bhatt, Valerie I. Brown, Paul Castillo, Jan Cerny, Edward A. Copelan, Charles Craddock, Bhagirathbhai Dholaria, Miguel Angel Diaz Perez, Christen L. Ebens, Robert Peter Gale, Siddhartha Ganguly, Lohith Gowda, Michael R. Grunwald, Shahrukh Hashmi, Gerhard C. Hildebrandt, Madiha Iqbal, Omer Jamy, Mohamed A. Kharfan-Dabaja, Nandita Khera, Hillard M. Lazarus, Richard Lin, Dipenkumar Modi, Sunita Nathan, Taiga Nishihori, Sagar S. Patel, Attaphol Pawarode, Wael Saber, Akshay Sharma, Melhem Solh, John L. Wagner, Trent Wang, Kirsten M. Williams, Lena E. Winestone, Baldeep Wirk, Amer Zeidan, Christopher S. Hourigan, Mark Litzow, Partow Kebriaei, Marcos de Lima, Kristin Page, Daniel J. Weisdorf
Publikováno v:
Leukemia. 37:1006-1017
Publikováno v:
Cancer Management and Research
Platelet-derived growth factor-beta (PDGFRB) gene maps for the receptor tyrosine kinase PDGRFβ. PDGFRB gene fusions have been implicated in multiple myeloid and lymphoid neoplasms and have shown exquisite sensitivity to tyrosine kinase inhibitors. W
Autor:
Lloyd Hutchinson, Muthalagu Ramanathan, Patricia M. Miron, Anne W. Higgins, Asiri Ediriwickrema, Jonathan M. Gerber, Jan Cerny, Maxwell R Lloyd, Qiming Shi, Karl Simin, Shyam A. Patel
Publikováno v:
Leukemia & Lymphoma. 62:3348-3360
TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia have dismal outcomes. Here, we define the clinico-genomic landscape of TP53 disruptions in 40 patients and employ clonal dynamic modeling to map the mutational hierarchy against clinic
Autor:
Benjamin Chen, Vladislav V. Makarenko, Rajneesh Nath, Jan Cerny, Muthalagu Ramanathan, William Selove, Keith Tomaszewicz, Lloyd Hutchinson, Jacob R. Bledsoe, Bruce A. Woda, Xiuling Meng
Publikováno v:
eJHaem. 2:514-519
Publikováno v:
Leukemia & Lymphoma. 62:2022-2025
Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 25% of non-Hodgkin lymphoma cases [1]. Although often treatment-responsive, 30–40% of DLBCL patients develop refractory or relapsed ...
Autor:
Guru Subramanian Guru Murthy, Soyoung Kim, Zhen-Huan Hu, Noel Estrada-Merly, Muhammad Bilal Abid, Mahmoud Aljurf, Ulrike Bacher, Sherif M. Badawy, Amer Beitinjaneh, Chris Bredeson, Jean-Yves Cahn, Jan Cerny, Miguel Angel Diaz Perez, Nosha Farhadfar, Robert Peter Gale, Siddhartha Ganguly, Usama Gergis, Gerhard C. Hildebrandt, Michael R. Grunwald, Shahrukh Hashmi, Nasheed M. Hossain, Matt Kalaycio, Rammurti T. Kamble, Mohamed A. Kharfan-Dabaja, Betty Ky Hamilton, Hillard M. Lazarus, Jane Liesveld, Mark Litzow, David I. Marks, Hemant S. Murthy, Sunita Nathan, Aziz Nazha, Taiga Nishihori, Sagar S. Patel, Attaphol Pawarode, David Rizzieri, Bipin Savani, Sachiko Seo, Melhem Solh, Celalettin Ustun, Marjolein van der Poel, Leo F. Verdonck, Ravi Vij, Baldeep Wirk, Betul Oran, Ryotaro Nakamura, Bart Scott, Wael Saber
Publikováno v:
JAMA Oncology, 8(3), 404-411. American Medical Association
JAMA Oncol
JAMA Oncol
Importance Matched sibling donors (MSDs) are preferred for allogeneic hematopoietic cell transplantation (allo-HCT) in myelodysplastic syndrome even if they are older. However, whether older MSDs or younger human leukocyte antigen-matched unrelated d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::639bda17f43fbaee45fe98e0c1f19058
https://cris.maastrichtuniversity.nl/en/publications/7f0ea0f4-e0d2-4f89-b272-9faba5655f2c
https://cris.maastrichtuniversity.nl/en/publications/7f0ea0f4-e0d2-4f89-b272-9faba5655f2c
Autor:
Alois Gratwohl, Jason Law, David Szwajcer, Jean A. Yared, Bronwen E. Shaw, Ruta Brazauskas, Amer Beitinjaneh, Matthew L. Ulrickson, Hisham Abdel-Azim, Sara Beattie, Navneet S. Majhail, Shahrukh K. Hashmi, J. Douglas Rizzo, Wael Saber, Neel S. Bhatt, William A. Wood, Charles F. LeMaistre, Stephanie J. Lee, Bipin N. Savani, Sherif M. Badawy, Stefan O. Ciurea, Richard F. Olsson, David A. Rizzieri, Hasan Hashem, Sachiko Seo, Sanghee Hong, Jan Cerny, Akshay Sharma, Kyle Hebert, Hélène Schoemans, Hillard M. Lazarus, Ayami Yoshimi, Rammurti T. Kamble, Siddhartha Ganguly, Nosha Farhadfar, Theresa Hahn, Miguel Angel Diaz, Nandita Khera, Mahmoud Aljurf, Usama Gergis
Publikováno v:
Cancer
Cancer, vol 127, iss 4
Cancer, vol 127, iss 4
Background The association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow
Publikováno v:
Acta Haematologica. 144:297-301
Acute myeloid leukemia (AML) is a stem cell malignancy that originates in the bone marrow and involves the peripheral blood. Extramedullary AML is rarer, but it is most commonly associated with the former French-American-British (FAB) subtypes M4 or
Autor:
Ayman Saad, Gregory A. Hale, Richard F. Olsson, Guillermo Garcia-Manero, Jane L. Liesveld, Farhad Ravandi, Kwang Woo Ahn, Sachiko Seo, Jan Cerny, Aaron T. Gerds, Michael R. Grunwald, Rammuriti T. Kamble, Taiga Nishihori, Melhem Solh, Xiao Lin, Srdan Verstovsek, Richard E. Champlin, Bipin N. Savani, Ronald Sobecks, Gorgun Akpek, Edwin P. Alyea, Mark R. Litzow, Celalettin Ustun, Hans C. Lee, Xuelin Huang, Andrew Daly, Mahmoud Aljurf, Ulrike Bacher, Hagop M. Kantarjian, Zachariah DeFilipp, Wael Saber, Jorge E. Cortes, Bei Hu, Tamila L. Kindwall-Keller, Bart L. Scott, Marcos de Lima, Nasheed Hossain, Uday R. Popat, Zhen-Huan Hu, Yoshihiro Inamoto, Mohamed A. Kharfan-Dabaja, David I. Marks, Jack W. Hsu, Rebecca S. S. Tidwell, Baldeep Wirk, Elias Jabbour
Publikováno v:
Leukemia & Lymphoma. 61:2811-2820
While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residual life expectancy (RLE) for patients initially diagnosed with CP CML based on timing of alloHCT or
Autor:
Witold B. Rybka, Mark R. Litzow, Hillard M. Lazarus, Jan Cerny, Xin Victoria Wang, Jacob M. Rowe, Martin S. Tallman, Stephen A. Strickland
Publikováno v:
Leukemia & Lymphoma. 61:2191-2199
High-dose cytarabine (HiDAC) consolidation for acute myeloid leukemia (AML) induces transient profound myelosuppression and potential morbidity/mortality. PrE0901 was a phase I multi-center trial evaluating the safety/toxicity of eltrombopag in AML p